Clinical Trial Detail

NCT ID NCT02876302
Title Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Dana-Farber Cancer Institute
Indications

triple-receptor negative breast cancer

Therapies

Cyclophosphamide + Doxorubicin + Paclitaxel + Ruxolitinib

Age Groups: senior adult

No variant requirements are available.